Cancer Immunology, Immunotherapy

, Volume 61, Issue 9, pp 1547–1564

Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application

  • Sophia N. Karagiannis
  • Debra H. Josephs
  • Panagiotis Karagiannis
  • Amy E. Gilbert
  • Louise Saul
  • Sarah M. Rudman
  • Tihomir Dodev
  • Alexander Koers
  • Philip J. Blower
  • Christopher Corrigan
  • Andrew J. Beavil
  • James F. Spicer
  • Frank O. Nestle
  • Hannah J. Gould
Symposium-in-writing paper

DOI: 10.1007/s00262-011-1162-8

Cite this article as:
Karagiannis, S.N., Josephs, D.H., Karagiannis, P. et al. Cancer Immunol Immunother (2012) 61: 1547. doi:10.1007/s00262-011-1162-8

Abstract

Therapeutic antibodies have revolutionised treatment of some cancers and improved prognosis for many patients. Over half of those available are approved for haematological malignancies, but efficacious antibodies for solid tumours are still urgently needed. Clinically available antibodies belong to the IgG class, the most prevalent antibody class in human blood, while other classes have not been extensively considered. We hypothesised that the unique properties of IgE, a class of tissue-resident antibodies commonly associated with allergies, which can trigger powerful immune responses through strong affinity for their particular receptors on effector cells, could be employed for passive immunotherapy of solid tumours such as ovarian and breast carcinomas. Our laboratory has examined this concept by evaluating two chimaeric antibodies of the same specificity (MOv18) but different isotype, an IgG1 and an IgE against the tumour antigen folate receptor α (FRα). The latter demonstrates the potency of IgE to mount superior immune responses against tumours in disease-relevant models. We identified Fcε receptor-expressing cells, monocytes/macrophages and eosinophils, activated by MOv18 IgE to kill tumour cells by mechanisms such as ADCC and ADCP. We also applied this notion to a marketed therapeutic, the humanised IgG1 antibody trastuzumab and engineered an IgE counterpart, which retained the functions of trastuzumab in restricting proliferation of HER2/neu-expressing tumour cells but also activated effector cells to kill tumour cells by different mechanisms. On-going efficacy, safety evaluations and future first-in-man clinical studies of IgE therapeutics constitute key metrics for this concept, providing new scope for antibody immunotherapies for solid tumours.

Keywords

IgETumour immunotherapyFRα/FBPMonocytes/macrophagesMOv18 IgEAllergooncology symposium-in-writingHER2/neuIgGTrastuzumabBasophilsEosinophilsMast cellsSolid tumoursADCCADCPOvarian carcinomasBreast carcinomas

Abbreviations

FBP/FRα

Folate-binding protein/folate receptor alpha

ADCC

Antibody-dependent cell-mediated cytotoxicity

ADCP

Antibody-dependent cell-mediated phagocytosis

FcεRI

Fc epsilon Receptor I

HER2/neu

Human epidermal growth factor receptor 2

FcεRIα

FcεRI alpha

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Sophia N. Karagiannis
    • 1
    • 2
  • Debra H. Josephs
    • 1
    • 2
  • Panagiotis Karagiannis
    • 1
    • 2
  • Amy E. Gilbert
    • 1
    • 2
  • Louise Saul
    • 1
    • 2
  • Sarah M. Rudman
    • 4
  • Tihomir Dodev
    • 3
    • 5
  • Alexander Koers
    • 6
  • Philip J. Blower
    • 6
  • Christopher Corrigan
    • 5
  • Andrew J. Beavil
    • 3
    • 5
  • James F. Spicer
    • 4
  • Frank O. Nestle
    • 1
    • 2
  • Hannah J. Gould
    • 3
  1. 1.NIHR Biomedical Research Centre at Guy’s and St. Thomas’s Hospitals and King’s College LondonLondonUK
  2. 2.Cutaneous Medicine and Immunotherapy Unit, St. John’s Institute of Dermatology, Division of Genetics and Molecular Medicine, King’s College London School of Medicine, Guy’s TowerGuy’s HospitalLondonUK
  3. 3.Randall Division of Cell and Molecular Biophysics, New Hunt’s HouseKing’s College LondonLondonUK
  4. 4.Section of Research Oncology, Division of Cancer Studies, King’s College London School of MedicineGuy’s HospitalLondonUK
  5. 5.Division of Asthma, Allergy and Lung Biology, MRC and Asthma UK Centre for Allergic Mechanisms of Asthma, King’s College London School of MedicineGuy’s HospitalLondonUK
  6. 6.Department of Imaging Chemistry & Biology, Division of Imaging Sciences and Biomedical Engineering, King’s College London, The Rayne InstituteSt Thomas’ HospitalLondonUK